跳至主要内容
临床试验/NCT06641934
NCT06641934尚未招募不适用

Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients

The First Affiliated Hospital of Xinxiang Medical College1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2024年10月20日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
1,000
试验地点
1
主要终点
Incidence of chemotherapy-related myelosuppression and current status of prophylactic therapy

研究概览

简要总结

Current Survey on Chemotherapy-Related Myelosuppression and Clinical Management in Chinese County-level Tumor Patients

详细描述

The purpose of this research project was to gain an in-depth understanding of the myelosuppression of cancer patients in counties in China after receiving chemotherapy-based treatment regimens through a cross-sectional survey with the help of an online questionnaire system, and to investigate doctors' cognition and treatment concepts of chemotherapy-induced myelosuppression. 1. Fill the gaps in relevant domestic research and provide basic data for follow-up longitudinal studies and intervention studies; 2. Analyze the influencing factors and coping strategies of chemotherapy-induced bone marrow suppression from multiple perspectives, so as to provide reference for improving the knowledge level and treatment level of patients and doctors; 3. Provide more scientific guidance and suggestions for chemotherapy for cancer patients, help patients reduce the harm of bone marrow suppression, improve the survival rate and quality of life of patients, and also provide strong data support for the prevention and treatment of tumors and promote the development of cancer prevention and treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Incidence of chemotherapy-related myelosuppression and current status of prophylactic therapy

时间窗: 2024.09-2025.09

The incidence and treatment status of chemotherapy-related myelosuppression were investigated in the form of questionnaires Like what: 1. Did bone marrow suppression occur after the previous cycle of chemotherapy? (First chemotherapy/occurrence/non-occurrence) 2. Did CIM (chemotherapy-induced myelosuppression) occur during this chemotherapy? (Multiple selections allowed) 3. Survey questions about existing CIM therapeutic drugs

次要结局

  • Incidence of chemotherapy-related myelosuppression(2024.09-2025.09)
  • the rate and economic burden of neutropenia treatment during chemotherapy treatment(2024.09-2025.09)
  • the incidence of thrombocytopenia and the rate of primary and secondary prevention and treatment during chemotherapy treatment(2024.09-2025.09)
  • thrombocytopenia treatment rate and economic burden during chemotherapy treatment(2024.09-2025.09)
  • the incidence and treatment rate of anemia during chemotherapy treatment;(2024.09-2025.09)
  • Long and/or short acting granulocyte colony-stimulating factor (G-CSF) and/or Chinese patent medicine usage rate and application scenario cost analysis(2024.09-2025.09)
  • Recombinant human interleukin-11 and/or thrombopoietin (TPO) and/or thrombopoietin receptor agonists (TPO-RA) and/or cost analysis of application scenarios(2024.09-2025.09)
  • Erythropoietin and/or iron and/or Chinese patent medicine usage rate and application scenario cost analysis(2024.09-2025.09)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验